Choosing an insulin regimen: a patient-centered approach
AbstractChoosing the best insulin regimen for patients with type 1 diabetes mellitus (T1DM) requires the most personalized and thoughtful approach.
It has been demonstrated that the continuous subcutaneous insulin infusion (CSII) using insulin pump has many advantages. Nevertheless, this method of insulin therapy is unacceptable for some patients. That is why today the emphasis is on personalized selection of therapy.
The possibilities for a patient-centered approach in T1DM have significantly expanded due to the new generation of insulin analogues. In this regard, it is interesting to discuss the presented in this review publications dedicated to the possibilities of various insulin regimens and the latest generations of insulin analogues advantages for using in different therapy regimens.
The BIGLEAP study has shown that insulin degludec can provide an acceptable alternative to the basal pump insulin therapy regimen for patients with T1DM who cannot or do not want to use an insulin pump. The authors of the second work mentioned in this review presented the results of a meta-analysis devoted to the study of the comparative effectiveness of fast-acting insulin aspart and insulin aspart in the CSII.
Keywords:type 1 diabetes mellitus; multiple insulin injections; insulin pump; insulin degludec; fast-acting insulin aspart; patient-centered approach
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. Thematic publications reviewing, writing of the article, approval of the manuscript for publication – Pashkova E.Yu.; writing and design of the article, thematic publications reviewing, data processing, analysis and interpretation – Antsiferova D.M.; thematic publications reviewing, writing of the article, data processing, analysis and interpretation – Mitchenko Yu.I.
Для цитирования: Pashkova E.Yu., Antsiferova D.M., Mitchenko Yu.I. Choosing an insulin regimen: a patient-centered approach. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (4): 78–86. DOI: https://doi.org/10.33029/2304-9529-2023-12-4-78-86 (in Russian)
References
1. Cleary P.A., Orchard T.J., Genuth S., et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study. Diabetes. 2006; 55: 3556–65.
2. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353: 2643–53.
3. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016; 39: 1378–83.
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287: 2563–9.
5. Algorithms for specialized medical care for patients with diabetes mellitus. In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). 11th issue. Moscow, 2023. (in Russian)
6. Dedov I.I., Shestakova M.V., Mayorov A. Yu. Clinical guidelines “Type 1 diabetes mellitus in adults.” Approved Russian Association of Endocrinologists, 2022. URL: https://cr.minzdrav.gov.ru/recomend/286_2 (in Russian)
7. Clinical guidelines “Type 1 diabetes mellitus in children”. Approved Russian Association of Endocrinologists, 2022. URL: https://cr.minzdrav.gov.ru/recomend/287_2 (in Russian)
8. American Diabetes Association: Standards of Medical Care in Diabetes – 2023. 7. Diabetes Technology. Diabetes Care. 2023; 46 (suppl 1): S 111–27. DOI: https://doi.org/10.2337/dc23-S007
9. Lane W., Bailey T.S., Gerety G., et al.; Group Information; SWITCH 1. Effect of insulin degludec vs insulin glargine U 100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017; 318: 33–44.
10. Home P.D., Bergenstal R.M., Bolli G.B., et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015; 38: 2217–25.
11. Russell-Jones D., Bode B.W., De Block C., et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017; 40: 943–50.
12. Klaff L., Cao D., Dellva M.A., et al. Ultra-rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020; 22: 1799–807.
13. Blevins T., Zhang Q., Frias J.P., Jinnouchi H.; PRONTO-T2D Investigators. Randomized doubleblind clinical trial comparing ultra-rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care. 2020; 43: 2991–8.
14. Yeh H.C., Brown T.T., Maruthur N., et al. Comparative effectiveness, and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012; 157: 336–47.
15. Holt R.I.G., DeVries J.H., Hess-Fischl A., et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021; 44: 2589–625.
16. Lane W.S., Weinrib S.L., Lawrence M.J., et al. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): a single-center, open-label, randomized, crossover trial. Endocr Pract. 2022; 28: 165–72.
17. Zhang X.W., Zhang X.L., Xu B., Kang L.N. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2018; 55 (5): 429–41.
18. Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979; 8 (1): 7–20.
19. Fatourechi M.M., Kudva Y.C., Murad M.H., et al. Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009; 94 (3): 729–40.
20. Zhang E., Cao Z. Tissue response to subcutaneous infusion catheter. J Diabetes Sci Technol. 2020; 14 (2): 226e232.
21. Foster N.C., Beck R.W., Miller K.M., et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther. 2019; 21 (2): 66–72.
22. Haahr H., Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014; 53 (9): 787–800.
23. Aronson R., Li A., et al. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial. Lancet Diabetes Endocrinol. 2020; 8 (6): 511–23.
24. Dutta D., Mohindra R., Mahajan K., Sharma M. Performance of fast-acting aspart insulin as compared to aspart insulin in insulin pump for managing type 1 diabetes mellitus: a meta-analysis. Diabetes Metab J. 2023; 47 (1): 72–81.
25. Heise T., Pieber T.R., Danne T., et al. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017; 56: 551–9.
26. Rys P., Pankiewicz O., Lach K., Kwaskowski A., et al. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab. 2011; 37: 190–200.
27. Avgerinos I., Papanastasiou G., et al. Ultra-rapid-acting insulins for adults with diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2021; 23: 2395–401.
28. Garg S.K., Weinzimer S.A., Tamborlane W.V., Buckingham B.A., et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017; 19: 155–63.
29. Heise T., Hovelmann U., Brondsted L., Adrian C.L., et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015; 17: 682–8.
30. Haahr H., Heise T. Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. Clin Pharmacokinet. 2020; 59: 155–72.
31. Ozer K., Cooper A.M., Ahn L.P., Waggonner C.R., et al. Fast acting insulin aspart compared with insulin aspart in the Medtronic 670G hybrid closed loop system in type 1 diabetes: an open label crossover study. Diabetes Technol Ther. 2021; 23: 286–92.
32. Klonoff D.C., Evans M.L., Lane W., Kempe H.P., et al. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes Obes Metab. 2019; 21: 961–7.
33. Boughton C.K., Hartnell S., Thabit H., Poettler T., et al. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab. 2021; 23: 1389–96.
34. Hsu L., Buckingham B., Basina M., Ekhlaspour L., et al. Fast-acting insulin aspart use with the MiniMedTM 670G System. Diabetes Technol Ther. 2021; 23: 1–7.
35. Evans M., Wilkinson M., Giannpolou A. Fast-acting insulin aspart: the rationale for a new mealtime insulin. Diabetes Ther. 2019; 10: 1793–800.